Suppr超能文献

一株携带针对生物膜裂解酶的新型金黄色葡萄球菌噬菌体的鉴定。

Characterization of a New Staphylococcus aureus Kayvirus Harboring a Lysin Active against Biofilms.

机构信息

LIBRO-Laboratório de Investigação em Biofilmes Rosário Oliveira, Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4700-057, Braga, Portugal.

出版信息

Viruses. 2018 Apr 7;10(4):182. doi: 10.3390/v10040182.

Abstract

is one of the most relevant opportunistic pathogens involved in many biofilm-associated diseases, and is a major cause of nosocomial infections, mainly due to the increasing prevalence of multidrug-resistant strains. Consequently, alternative methods to eradicate the pathogen are urgent. It has been previously shown that polyvalent staphylococcal kayviruses and their derived endolysins are excellent candidates for therapy. Here we present the characterization of a new bacteriophage: vB_SauM-LM12 (LM12). LM12 has a broad host range (>90%; 56 strains tested), and is active against several MRSA strains. The genome of LM12 is composed of a dsDNA molecule with 143,625 bp, with average GC content of 30.25% and codes for 227 Coding Sequences (CDSs). Bioinformatics analysis did not identify any gene encoding virulence factors, toxins, or antibiotic resistance determinants. Antibiofilm assays have shown that this phage significantly reduced the number of viable cells (less than one order of magnitude). Moreover, the encoded endolysin also showed activity against biofilms, with a consistent biomass reduction during prolonged periods of treatment (of about one order of magnitude). Interestingly, the endolysin was shown to be much more active against stationary-phase cells and suspended biofilm cells than against intact and scraped biofilms, suggesting that cellular aggregates protected by the biofilm matrix reduced protein activity. Both phage LM12 and its endolysin seem to have a strong antimicrobial effect and broad host range against , suggesting their potential to treat biofilm infections.

摘要

金黄色葡萄球菌是与许多生物膜相关疾病有关的最重要的机会性病原体之一,也是医院感染的主要原因,主要是由于多药耐药株的日益流行。因此,迫切需要替代方法来消灭病原体。先前已经表明,多价葡萄球菌噬菌体及其衍生的内溶素是治疗的理想候选物。在这里,我们介绍了一种新噬菌体:vB_SauM-LM12(LM12)。LM12 的宿主范围很广(>90%;测试了 56 株),对几种耐甲氧西林金黄色葡萄球菌(MRSA)菌株有效。LM12 的基因组由一个 dsDNA 分子组成,长度为 143625 bp,平均 GC 含量为 30.25%,编码 227 个编码序列(CDS)。生物信息学分析未发现任何编码毒力因子、毒素或抗生素耐药决定因子的基因。抗生物膜测定表明,该噬菌体显著减少了活菌数量(减少一个数量级以下)。此外,编码的内溶素也对生物膜表现出活性,在长时间的治疗过程中(约一个数量级),生物量持续减少。有趣的是,与完整和刮除的生物膜相比,内溶素对静止期细胞和悬浮生物膜细胞的活性更高,这表明生物膜基质保护的细胞聚集体降低了蛋白质的活性。噬菌体 LM12 和其内溶素似乎对金黄色葡萄球菌具有很强的抗菌作用和广泛的宿主范围,表明它们具有治疗生物膜感染的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8e2/5923476/4bba266d6ac8/viruses-10-00182-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验